Literature DB >> 25452283

Identification of a wide range of motifs inhibitory to shiga toxin by affinity-driven screening of customized divalent peptides synthesized on a membrane.

Mihoko Kato1, Miho Watanabe-Takahashi1, Eiko Shimizu1, Kiyotaka Nishikawa2.   

Abstract

Shiga toxin (Stx), a major virulence factor of enterohemorrhagic Escherichia coli, binds to target cells through a multivalent interaction between its B-subunit pentamer and the cell surface receptor globotriaosylceramide, resulting in a remarkable increase in its binding affinity. This phenomenon is referred to as the "clustering effect." Previously, we developed a multivalent peptide library that can exert the clustering effect and identified Stx neutralizers with tetravalent peptides by screening this library for high-affinity binding to the specific receptor-binding site of the B subunit. However, this technique yielded only a limited number of binding motifs, with some redundancy in amino acid selectivity. In this study, we established a novel technique to synthesize up to 384 divalent peptides whose structures were customized to exert the clustering effect on the B subunit on a single cellulose membrane. By targeting Stx1a, a major Stx subtype, the customized divalent peptides were screened to identify high-affinity binding motifs. The sequences of the peptides were designed based on information obtained from the multivalent peptide library technique. A total of 64 candidate motifs were successfully identified, and 11 of these were selected to synthesize tetravalent forms of the peptides. All of the synthesized tetravalent peptides bound to the B subunit with high affinities and effectively inhibited the cytotoxicity of Stx1a in Vero cells. Thus, the combination of the two techniques results in greatly improved efficiency in identifying biologically active neutralizers of Stx.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25452283      PMCID: PMC4292467          DOI: 10.1128/AEM.03517-14

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  32 in total

1.  Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands.

Authors:  P I Kitov; J M Sadowska; G Mulvey; G D Armstrong; H Ling; N S Pannu; R J Read; D R Bundle
Journal:  Nature       Date:  2000-02-10       Impact factor: 49.962

2.  Structure of the shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3.

Authors:  H Ling; A Boodhoo; B Hazes; M D Cummings; G D Armstrong; J L Brunton; R J Read
Journal:  Biochemistry       Date:  1998-02-17       Impact factor: 3.162

3.  A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7.

Authors:  Kiyotaka Nishikawa; Koji Matsuoka; Eiji Kita; Noriko Okabe; Masashi Mizuguchi; Kumiko Hino; Shinobu Miyazawa; Chisato Yamasaki; Junken Aoki; Sachio Takashima; Yoshio Yamakawa; Masahiro Nishijima; Daiyo Terunuma; Hiroyoshi Kuzuhara; Yasuhiro Natori
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

4.  Rescue from lethal Shiga toxin 2-induced renal failure with a cell-permeable peptide.

Authors:  Deborah J Stearns-Kurosawa; Valta Collins; Scott Freeman; Diann Debord; Kiyotaka Nishikawa; Sun-Young Oh; Caitlin S Leibowitz; Shinichiro Kurosawa
Journal:  Pediatr Nephrol       Date:  2011-05-21       Impact factor: 3.714

5.  Shiga toxin subtypes display dramatic differences in potency.

Authors:  Cynthia A Fuller; Christine A Pellino; Michael J Flagler; Jane E Strasser; Alison A Weiss
Journal:  Infect Immun       Date:  2011-01-03       Impact factor: 3.441

Review 6.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.

Authors:  Phillip I Tarr; Carrie A Gordon; Wayne L Chandler
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

7.  Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7.

Authors:  Marie E Fraser; Masao Fujinaga; Maia M Cherney; Angela R Melton-Celsa; Edda M Twiddy; Alison D O'Brien; Michael N G James
Journal:  J Biol Chem       Date:  2004-04-09       Impact factor: 5.157

8.  Hemorrhagic colitis associated with a rare Escherichia coli serotype.

Authors:  L W Riley; R S Remis; S D Helgerson; H B McGee; J G Wells; B R Davis; R J Hebert; E S Olcott; L M Johnson; N T Hargrett; P A Blake; M L Cohen
Journal:  N Engl J Med       Date:  1983-03-24       Impact factor: 91.245

Review 9.  Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections.

Authors:  J C Paton; A W Paton
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

10.  Lessons Learned From Outbreaks of Shiga Toxin Producing Escherichia coli.

Authors:  Susanne Hauswaldt; Martin Nitschke; Friedhelm Sayk; Werner Solbach; Johannes K-M Knobloch
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

View more
  3 in total

1.  Affinity-Based Screening of Tetravalent Peptides Identifies Subtype-Selective Neutralizers of Shiga Toxin 2d, a Highly Virulent Subtype, by Targeting a Unique Amino Acid Involved in Its Receptor Recognition.

Authors:  Takaaki Mitsui; Miho Watanabe-Takahashi; Eiko Shimizu; Baihao Zhang; Satoru Funamoto; Shinji Yamasaki; Kiyotaka Nishikawa
Journal:  Infect Immun       Date:  2016-08-19       Impact factor: 3.441

Review 2.  Shiga Toxin Therapeutics: Beyond Neutralization.

Authors:  Gregory Hall; Shinichiro Kurosawa; Deborah J Stearns-Kurosawa
Journal:  Toxins (Basel)       Date:  2017-09-19       Impact factor: 4.546

3.  The inducible amphisome isolates viral hemagglutinin and defends against influenza A virus infection.

Authors:  Jumpei Omi; Miho Watanabe-Takahashi; Katsura Igai; Eiko Shimizu; Ching-Yi Tseng; Tomohiro Miyasaka; Tsuyoshi Waku; Shinichiro Hama; Rieka Nakanishi; Yuki Goto; Yuri Nishino; Atsuo Miyazawa; Yasuhiro Natori; Makoto Yamashita; Kiyotaka Nishikawa
Journal:  Nat Commun       Date:  2020-01-09       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.